Since Blachere and colleagues discovered that the HSP70–peptide complex leads to an antigen-specific CD8+ T cell response in 1997, a new research avenue has been opened for the use of HSP70 as an adjuvant in cancer vaccine therapies [122,123]. The gene discussed is HSPA1A; the disease is cancer.